EA200802398A1 - Гранулы липоевой кислоты - Google Patents

Гранулы липоевой кислоты

Info

Publication number
EA200802398A1
EA200802398A1 EA200802398A EA200802398A EA200802398A1 EA 200802398 A1 EA200802398 A1 EA 200802398A1 EA 200802398 A EA200802398 A EA 200802398A EA 200802398 A EA200802398 A EA 200802398A EA 200802398 A1 EA200802398 A1 EA 200802398A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lipoic acid
preparation
acid
treatment
granules
Prior art date
Application number
EA200802398A
Other languages
English (en)
Other versions
EA021501B1 (ru
Inventor
Луиджи Болтри
Флавио Фабиани
Луиджи Мапелли
Аннибале Сальви
Паоло Магри
Антонио Нарди
Флавио Виллани
Original Assignee
Еуранд Фармасьютикалс Лимитид
Лабораторио Химико Интернационале С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Еуранд Фармасьютикалс Лимитид, Лабораторио Химико Интернационале С.П.А. filed Critical Еуранд Фармасьютикалс Лимитид
Publication of EA200802398A1 publication Critical patent/EA200802398A1/ru
Publication of EA021501B1 publication Critical patent/EA021501B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D339/00—Heterocyclic compounds containing rings having two sulfur atoms as the only ring hetero atoms
    • C07D339/02—Five-membered rings
    • C07D339/04—Five-membered rings having the hetero atoms in positions 1 and 2, e.g. lipoic acid
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Saccharide Compounds (AREA)
  • Processes Of Treating Macromolecular Substances (AREA)

Abstract

Настоящее изобретение относится к средствам, основанным на липоевой кислоте или ее аналогах. 1,2-Дитиолан-3-пентиновая кислота (обычно известная как липоевая или тиоктиновая кислота) является активным компонентом с антиоксидантной активностью, который используется для лечения ряда заболеваний, включая болезни печени и желчной системы, полинейропатии, диабетические полинейропатии, вирусные инфекции, гиперхолистеринемию, дислипидемию, болезни почек, болезнь Альцгеймера, онкология и др. Это соединение улучшает обмен веществ и используется в качестве поддерживающего лечения в некоторых фармакологических способах лечения или терапии, как, например, в химиотерапии или у пациентов, подверженных циклам гемодиализа, или у пациентов, проходящих детоксикационное лечение (детоксикацию). Цель настоящего изобретения - использование гранулы (pellet) для приготовления лекарства, применимого при лечении патологических заболеваний, реагирующих на лечение липоевой кислотой, а также использование этих гранул в качестве питательных (пищевых) добавок и для их приготовления. В настоящем изобретении описываются гранулы липоевой кислоты, состоящие из инертных ядер, покрытых липоевой кислотой (активные ядра) и далее покрытых сначала полимерным покрытием с изолирующей функцией и затем вторым полимерным покрытием, а также различные варианты их приготовления и подготовки. Формулы (составы) для пищевого использования также являются целью этого изобретения. Гранулы липоевой кислоты можно использовать в пищевой промышленности как питательные добавки для конкретного пищевого продукта, например для пищевого продукта с кислым рН.
EA200802398A 2006-05-25 2007-05-25 Гранулы липоевой кислоты EA021501B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001024A ITMI20061024A1 (it) 2006-05-25 2006-05-25 Pellet a base di acido lipoico
PCT/EP2007/055124 WO2007138022A2 (en) 2006-05-25 2007-05-25 Lipoic acid pellets

Publications (2)

Publication Number Publication Date
EA200802398A1 true EA200802398A1 (ru) 2009-06-30
EA021501B1 EA021501B1 (ru) 2015-07-30

Family

ID=38446014

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200802398A EA021501B1 (ru) 2006-05-25 2007-05-25 Гранулы липоевой кислоты

Country Status (11)

Country Link
US (1) US8722096B2 (ru)
EP (1) EP2034974B1 (ru)
JP (2) JP5491859B2 (ru)
AU (1) AU2007267159B2 (ru)
BR (1) BRPI0712517A2 (ru)
CA (1) CA2653403C (ru)
EA (1) EA021501B1 (ru)
IT (1) ITMI20061024A1 (ru)
MX (1) MX2008015011A (ru)
NZ (1) NZ573756A (ru)
WO (1) WO2007138022A2 (ru)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
DE102007038849A1 (de) 2007-08-16 2009-02-19 Adscil Gmbh Verwendung von R(+)-alpha-Liponsäure zur Behandlung der kryptogenen Neuropathie
ITMI20072051A1 (it) * 2007-10-23 2009-04-24 Chimico Internaz S P A In Brev Composizione a base di pellet di acido lipoico
ITMI20072427A1 (it) 2007-12-24 2009-06-25 I P S Internat Products & Ser Matrce polimerica polivalente a immediata disgregazione per prodotti solidi per uso orale a rilascio modificato e metodo per la sua preparazione
ITMI20111286A1 (it) 2011-07-11 2013-01-12 Laboratorio Chimico Int Spa Nuova forma cristallina
PL3244885T3 (pl) * 2015-01-13 2019-08-30 Lo.Li. Pharma S.R.L. Kwas liponowy do leczenia lub zapobiegania zagrożeniu poronieniem lub przedwczesnym porodem
CN104688705B (zh) * 2015-02-09 2017-07-25 武汉泽智生物医药有限公司 一种α‑硫辛酸缓释片及其制备方法
CN106905478B (zh) * 2017-04-19 2018-09-18 贵州大学 一种α-硫辛酸分子印迹聚合物及其制备方法
CN110229138B (zh) * 2018-03-05 2022-08-02 华东理工大学 硫辛酸球形粒子及其制备方法和应用
CN108606958B (zh) * 2018-05-09 2020-12-04 南京海融医药科技股份有限公司 一种右硫辛酸赖氨酸盐肠溶片及其制备方法
TR201918013A2 (tr) * 2019-11-19 2021-06-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Propi̇veri̇n veya propi̇veri̇ni̇n farmasöti̇k olarak kabul edi̇lebi̇li̇r bi̇r tuzunu i̇çeren pellet kompozi̇syonu
EP4061369A4 (en) 2019-11-19 2024-04-10 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi PHARMACEUTICAL FORM COMPRISING AN ACIDIC SUBSTANCE
WO2021145625A1 (ko) * 2020-01-13 2021-07-22 한국유나이티드제약 주식회사 R-치옥트산 또는 이의 약학적으로 허용되는 염 및 장용코팅기제를 포함하는 약학조성물

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
JPH0774166B2 (ja) * 1987-02-06 1995-08-09 信越化学工業株式会社 徐放性被覆薬剤の製造方法
DE4433764A1 (de) 1994-09-22 1996-03-28 Asta Medica Ag Darreichungsformen enthaltend alpha-Liponsäure, feste Salze von R-Thioctsäure mit verbesserter Freisetzung und Bioverfügbarkeit
ES2094694B1 (es) * 1995-02-01 1997-12-16 Esteve Quimica Sa Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.
US6197340B1 (en) * 1998-05-28 2001-03-06 Medical Research Institute Controlled release lipoic acid
US6740341B1 (en) * 1998-11-25 2004-05-25 Cima Labs Inc. Taste masking rapid release coating system
IT1319195B1 (it) 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Processo per la produzione dell'acido r(+)alfa-lipoico.
IT1319194B1 (it) 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Processo per la produzione dell'acido tiottico racemo.
IT1319196B1 (it) 2000-10-10 2003-09-26 Laboratorio Chimico Int Spa Sintesi dell'acido r(+)alfa-lipoico.
US20020098247A1 (en) * 2000-11-02 2002-07-25 Komorowski James R. Methods and compositions for the improvement of insulin sensitivity, reduction of hyperglycemia, and reduction of hypercholesterolemia with chromium complexes and alpha lipoic acid
DE10159245A1 (de) * 2001-12-03 2003-06-18 Degussa Stabile, saure, wässrige Lösung enthaltend alpha-Liponsäure(-Derivate), Verfahren zu deren Herstellung sowie ihre Verwendung
CN1313030C (zh) * 2002-08-23 2007-05-02 帝斯曼知识产权资产管理有限公司 包含生物素的新颖的营养药物性组合物
MXPA04010956A (es) 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
ITMI20030831A1 (it) 2003-04-22 2004-10-23 Laboratorio Chimico Int Spa Sale basico dell'acido tiottico con la l-carnitina.
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
US7387793B2 (en) * 2003-11-14 2008-06-17 Eurand, Inc. Modified release dosage forms of skeletal muscle relaxants
US20060280843A1 (en) * 2005-02-23 2006-12-14 Ralf Jager Filler for a beverage container
ITMI20050466A1 (it) 2005-03-22 2006-09-23 Laboratorio Chimico Int Spa Processo di purificazione in acqua di acido tiottico
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico

Also Published As

Publication number Publication date
AU2007267159A1 (en) 2007-12-06
NZ573756A (en) 2011-04-29
US20090117232A1 (en) 2009-05-07
AU2007267159B2 (en) 2013-03-07
EA021501B1 (ru) 2015-07-30
MX2008015011A (es) 2009-03-09
EP2034974B1 (en) 2016-04-06
EP2034974A2 (en) 2009-03-18
WO2007138022A2 (en) 2007-12-06
JP2014040434A (ja) 2014-03-06
JP2009537611A (ja) 2009-10-29
CA2653403C (en) 2014-12-09
CA2653403A1 (en) 2007-12-06
WO2007138022A3 (en) 2008-01-31
ITMI20061024A1 (it) 2007-11-26
JP5491859B2 (ja) 2014-05-14
BRPI0712517A2 (pt) 2012-09-04
US8722096B2 (en) 2014-05-13

Similar Documents

Publication Publication Date Title
EA200802398A1 (ru) Гранулы липоевой кислоты
Streck et al. Chronic hyperhomocysteinemia provokes a memory deficit in rats in the Morris water maze task
TN2009000242A1 (en) Sulfonyl-phenyl-2h-[1,2,4]oxodiazol-5-one derivatives, processes for their preparation and their use as pharmaceuticals
TNSN06317A1 (en) Oxadiazolone derivatives as ppar delta agonists
MY148982A (en) Phenyl-1,2,4-oxadiazolone derivative with phenyl group, processes for their preparation and their use as pharmaceuticals
MA41150A (fr) Polymères de liaison aux protons pour administration orale
BRPI0512075A (pt) composto, processo para a preparação do mesmo, composição farmacêutica, uso de um composto, e, métodos para a produção de um efeito inibidor de b-raf, e de um efeito anticáncer em um animal de sangue quente, e para o tratamento de uma doença
ATE465164T1 (de) Triazolopyrazinverbindungen zur behandlung von degenerations- und entzündungskrankheiten
BRPI0514679A (pt) composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, métodos para produzir um efeito inibitório de b-raf e um efeito anticáncer em um animal de sangue quente, e para tratar uma doença ou condição
NO20064186L (no) Substituerte pyrazolin sammensetninger for a redusere triglycerider i blod
MX2010006647A (es) Piridil-n-[1,3,4]-tiadiazol-2-il-bencenosulfonamidas ciclicas, procedimientos para su preparacion y su uso como productos farmaceuticos.
BR112014030284A2 (pt) composto, e, composição farmacêutica
EA201200318A1 (ru) Гетероциклические оксимы
EA201200260A1 (ru) Гетероциклические гидразоны и их применение для лечения рака и воспаления
WO2007089857A3 (en) Substituted imidazole derivatives and their use as ptpase inhibitors
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
UA97090C2 (ru) Применение соли, соединения присоединения или комплексного соединения гуанидинуксусной кислоты как кормовой примеси или примеси к пищевому рациону
NZ607580A (en) N-heteroaryl compounds
ATE487720T1 (de) 5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
TW200621732A (en) Arylcycloalkyl-substituted alkanoic acid derivatives, processes for their preparation and their use as pharmaceuticals
AU2011208681A8 (en) Aqueous solution comprising 3 - quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
BR112014006223A2 (pt) 6-substituídas-3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas como tirosina quinase c-met
TW200510352A (en) Cycloalkyl substituted amino acid derivatives, processes for their freparation and their use as pharmaceuticals
NO20081681L (no) N-[1,3,4]-tiadiazol-2-yl-benzensulfonamider, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
WO2007098967A3 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU